ClinicalTrials.gg
Enrolling by invitationNCT06606340EVOLVEUpdated Nov 2, 2026

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

An observational study in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Enrolling by invitation at 23 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Sarepta Therapeutics, Inc. · Observational

How we know

Updated Nov 2, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Started
2019
with 2 others
Observational
2 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is one of 3 that started in 2019, is one of 2 observational ones, and was the 25th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
  • DMD
  • Post-marketing
  • Observational
  • Phase 4
  • Eteplirsen
  • Golodirsen
  • Casimersen
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants within each prescriber's practice who are receiving eteplirsen, golodirsen, or casimersen, in routine clinical practice, and who meet the study eligibility criteria and provide informed consent (either by the participant or through authorization by a legal guardian), will be invited to enroll into the study and will be followed according to the protocol.

Eligibility criteria

Key Inclusion Criteria:

  • Is willing to provide informed assent or consent (if applicable) and has a parent(s) or legal guardian(s) or is a participant ≥18 years of age who is (are) willing to provide for the participant to participate in the study and comply with study data collection procedures.
  • Has an established clinical diagnosis of DMD, as documented prior to screening by a genetic report.
  • Receiving, or initiating treatment with, eteplirsen, golodirsen, or casimersen at the time of observational study enrollment. Note: Participants with a prescription for eteplirsen, golodirsen, or casimersen at enrollment must initiate the exon-skipping therapy within 6 months of the date of enrollment or will no longer be eligible for this study. Note: Enrollment of eteplirsen participants has been completed, no additional participants will be enrolled.

Key Exclusion Criteria:

  • Is currently participating in any DMD interventional study at the time of this study enrollment.
  • Has declined to provide consent for collection of their genetic data.
  • Has a medical condition or confounding circumstances that, in the opinion of the Investigator, might compromise:

    1. The participant's ability to comply with the protocol-required procedures
    2. The participant's wellbeing or safety, and/or
    3. The clinical interpretability of the data collected from the participant.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Eteplirsen

    Drug: Eteplirsen

  • Golodirsen

    Drug: Golodirsen

  • Casimersen

    Drug: Casimersen

Interventions

  • No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.

    Also known as: AVI-4658, EXONDYS 51, EXONDYS

  • No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.

    Also known as: SRP-4053, VYONDYS 53

  • No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.

    Also known as: SRP-4045, AMONDYS 45

06

What researchers measure

Primary outcomes

  1. Loss of Ambulation (LOA)

    Time frame: Up to 5 years

  2. Time to Rise From the Floor (Supine to Stand)

    Time frame: Up to 5 years

  3. Time to Walk/Run 10 Meters

    Time frame: Up to 5 years

  4. Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A

    Time frame: Up to 5 years

  5. Pulmonary Function, as Measured by Forced Vital Capacity (FVC) (% Predicted)

    Time frame: Up to 5 years

  6. Cardiac Function, Including Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram (ECHO)

    Time frame: Up to 5 years

07

Study locations

23 sites
08

References and documents

Publications

  • Tian C, Grabich S, Veerapandiyan A, Scharf RJ, Santra S, Hornibrook S, Drummond K, Sehinovych I, Waldrop M. Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD. J Comp Eff Res. 2026 May;15(5):e250108. doi: 10.57264/cer-2025-0108. Epub 2026 Apr 10. PubMed 41961051 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2033, 179 months after the start.

Of 63 observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 120. This study's planned 179 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Sep 23, 2024
StartActual
Jan 7, 2019
Primary completionEst.
Dec 31, 2033
CompletionEst.
Dec 31, 2033
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Children's Hospital of Orange County - Main Campus - PIN · Orange, United States
  • University of Kansas Medical Center · Kansas City, United States
  • Montefiore Medical Center · The Bronx, United States
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    3 sites added
    Show 3 added (3 United States)
    • Children's Hospital of Orange County - Main Campus - PIN · Orange, United States
    • University of Kansas Medical Center · Kansas City, United States
    • Montefiore Medical Center · The Bronx, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06606340
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Jan 7, 2019
Primary completion
Dec 31, 2033 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion